top of page

[ 01 ]

Neuroscience Innovation

Our vision is to unlock the brain's potential through precision neuroscience. By targeting the underlying biological drivers of neurological disorders, we aim to transform patient outcomes and redefine the future of cognitive health.

Investment Milestones

2027

Preclinical completion — TQ-904

Complete preclinical trials for lead candidate TQ-904 and advance lead optimization of TQ-101.

2028

Clinical development begins — TQ-904

Initiate the Phase I clinical trial for TQ-904 and begin preclinical trials for TQ-101.

2029

Strategic partnership

Establish a partnership agreement with a leading Big Pharma company to advance our pipeline.

Investment Interest

Please select the stage of interest relevant to your inquiry.

Partner with Us

Unlocking the brain. Transforming lives. We invite visionary investors to join our mission of revolutionizing neuroscience and addressing the underlying causes of brain disorders.

bottom of page